MIPS

Description: For MEX 5, the patient must be seen at least twice: once at the time of diagnosis to document the pain scale, and a second time to assess any decrease in pain. In order to document the patient’s pain, you must use the standardized pain scale 1-10. This measure tracks pain levels from the first visit to the last. No specific treatment is required—any intervention that effectively reduces the patient's pain is acceptable, the hammer toe diagnosis must be a part of the claim. Treatments may include surgery, changes in shoe gear, padding, and debride corns.

REGCLR1 measures the improvement in function of the patients with a diagnosis of Heel Pain that have a reduction in pain after an intervention. No specific treatment is required to meet this measure; it simply requires a significant decrease in the patient's pain as a result of your intervention. Treatments may include custom orthotics, prefabricated orthotics, injections for heel pain, night splints, stretching, and physical therapy.

The Doctors and Clinicians Preview Period is open officially as of today, Tuesday, May 27, 2025. You can now preview your 2023 Quality Payment Program (QPP) performance information before it appears on the profile pages of clinicians and groups on the Medicare.gov compare tool and in the Provider Data Catalog (PDC). You can access the secure preview on the QPP website.

CMS has suspended Eight Improvement Activities for MIPS They intend to remove the activities from the program in future rulemaking.

Description: REGCLR3 measures the improvement in functions of patients with a diagnosis of Bunion Pain . Improvement is measured as a reduction in pain after an intervention. The patient must be treated, it is up to the medical provider to select the medically appropriate treatment. Treatments may include surgical intervention, shoe wear modifications, orthotics, and physical therapy.

Registry Clearinghouse

MIPS consists of 4 components Quality Reporting, Promoting interoperability, Improvement Activities and Cost. Another way to participate in MIPS is through an MVP. When reporting traditional MIPS you can report on individual measure or you can report a MIPS Value Pathway (MVP). Each year CMS updates the MIPS program.

2024 is winding down and we should be getting ready to report our 2024 performance to CMS. A common question that keeps popping up is: “Am I required to report MIPS for 2024?”

The MIPS automatic EUC policy doesn’t apply to MIPS eligible clinicians participating in MIPS as a group, subgroup, virtual group, or Alternative Payment Model (APM) Entity. However, groups, virtual groups, and APM Entities can request reweighting through the EUC Exception application. Subgroups will inherit any reweighting approved for their affiliated group; they can’t request reweighting independent of their affiliated group’s status.

Any bonus or penalty for your 2023 reporting period will be reflected in your 2024 Medicare Payments. CMS has released the scores and and payments for 2025 payment year.